Upsher-Smith Launches Clonidine Hydrochloride Extended-release Tablets

Maple Grove, Minn., Jan. 28, 2020 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Clonidine Hydrochloride Extended-Release Tablets in 0.1 mg strength. Upsher-Smith's product is AB1-rated to the branded product, KAPVAY® (clonidine hydrochloride) extended-release tablets*.

The clonidine hydrochloride extended-release tablet market had U.S. sales of approximately $30 million for the 12 months ending November 2019 according to IQVIA.

For questions about ordering, please call Upsher-Smith at 1-800-654-2299.

Please refer to the full Prescribing Information for Clonidine Hydrochloride Extended-Release Tablets here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.

You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting

About Upsher-Smith

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.

As Upsher-Smith celebrates its 100-year anniversary, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai Pharmaceutical Co., Ltd. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients they serve. For more information, visit

Source Upsher-Smith Laboratories, LLC

Elizabeth Likly
Kovak-Likly Communications

Web Site:

All Topics